Literature DB >> 25448208

Endoscopic endonasal transsphenoidal treatment for acromegaly: 2010 consensus criteria for remission and predictors of outcomes.

Ali Erdem Yildirim1, Mert Sahinoglu, Denizhan Divanlioglu, Fatih Alagoz, Ahmet Gurhan Gurcay, Ergun Daglioglu, Hilmi Onder Okay, Ahmed Deniz Belen.   

Abstract

AIM: Acromegaly is a chronic disorder characterized by enhanced growth hormone (GH) secretion and elevated insulin-like growth factor-I (IGF-I) levels, usually caused by pituitary adenomas. In this retrospective study, we reviewed our experience with endoscopic endonasal transsphenoidal surgery (EETS) with in remission rates using the 2010 consensus criteria, predictors of remission and associated complications.
MATERIAL AND METHODS: The authors retrospectively analyzed data from 56 acromegalic patients who underwent pure EETS. Tumors were classified according to size and suprasellar/parasellar extension. The criteria of remission were GH levels < 1 ng/mL randomly, < 0.4 ng/mL after oral glucose tolerance test and normal IGF-I levels for age and sex within the first 3 and 6 months after surgery.
RESULTS: Biochemical remission was achieved in 4 of 5 microadenomas (80%) and in 33 of 51 macroadenomas (64.7%). The total remission rate was 66.1% (37 of 56 adenomas). Age, gender and suprasellar extension did not affect the remission rate. However, cavernous sinus invasion, sphenoid sinus invasion and history of prior surgery were associated with lower rates of disease control.
CONCLUSION: EETS represents an effective and safe option for the treatment of patients with acromegaly. High disease control rates and a small number of complications are some of the most important points related to the technique.

Entities:  

Mesh:

Year:  2014        PMID: 25448208     DOI: 10.5137/1019-5149.JTN.11288-14.1

Source DB:  PubMed          Journal:  Turk Neurosurg        ISSN: 1019-5149            Impact factor:   1.003


  7 in total

1.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

Review 2.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.

Authors:  Amy A Swanson; Dana Erickson; Diane Mary Donegan; Sarah M Jenkins; Jamie J Van Gompel; John L D Atkinson; Bradley J Erickson; Caterina Giannini
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

Review 4.  The surgical treatment of acromegaly.

Authors:  Michael Buchfelder; Sven-Martin Schlaffer
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.

Authors:  Lian Duan; Huijuan Zhu; Bing Xing; Feng Gu
Journal:  BMC Endocr Disord       Date:  2017-09-06       Impact factor: 2.763

6.  Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.

Authors:  Tyler Cardinal; Casey Collet; Michelle Wedemeyer; Peter A Singer; Martin Weiss; Gabriel Zada; John D Carmichael
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-18       Impact factor: 5.555

7.  Radiological Knosp, Revised-Knosp, and Hardy-Wilson Classifications for the Prediction of Surgical Outcomes in the Endoscopic Endonasal Surgery of Pituitary Adenomas: Study of 228 Cases.

Authors:  Marta Araujo-Castro; Alberto Acitores Cancela; Carlos Vior; Eider Pascual-Corrales; Víctor Rodríguez Berrocal
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.